Acasti pharma reports last patient visit in trilogy 1 phase 3 trial of capre for the treatment of severe hypertriglyceridemia

Acasti pharma reports last patient visit in trilogy 1 phase 3 trial of capre for the treatment of severe hypertriglyceridemia.acasti pharma - expects last patient to complete final visit in trilogy 2 in early jan 2020, with topline results expected towards end of jan 2020.acasti pharma - if trilogy 1, trilogy 2 results are positive, co intends to file an nda by mid-2020 to obtain regulatory approval for capre in u.s..acasti pharma inc - on track to report topline results for trilogy 1 in dec 2019 and trilogy 2 in jan 2020.
ACST Ratings Summary
ACST Quant Ranking